- SEK1.29bn
- SEK1.20bn
- SEK128.95m
Brief: Carthesian Therapeutics Terminates Genovis Licence Agreement
Brief: Genovis Q4 EBITDA SEK 3.615 Million
Brief: Genovis Q3 EBITDA SEK 7.555 Million
Brief: Genovis Says Start Of Q3 Continues To Show Good Customer Activity
Brief: Genovis Q2 EBITDA at SEK 7.687 Million
Brief: Genovis Q1 Revenue Rises By 119%
Brief: Genovis Q1 EBITDA at SEK 45.1 Million
Brief: Genovis, Arcticzymes Technologies Enter Into Collaboration Agreement
Brief: Genovis Acquires IP Rights To Novel Enzymes For Applications Within Genomics
Brief: Genovis Q4 EBITDA Turns To Loss At SEK 5.9 Mln
Brief: Genovis Receives $4 Mln After Selecta Biosciences Sublicenses Xork Enzyme To Astellas Pharma
Brief: Genovis Q3 EBITDA Up At SEK 7 Mln
Brief: Genovis Q2 EBITDA Falls To SEK 2.1 Mln
Brief: Genovis Enters Licensing And Supply Agreement With New Bioprocess Customer
Brief: Genovis Enters Service Agreement With Evitria
Brief: Genovis Q1 EBITDA Up At SEK 11.7 Mln
Brief: Genovis Q4 EBITDA Rises To SEK 23.4 Mln
Brief: Genovis Q3 EBITDA Down At SEK 2.2 Mln
Brief: Selecta Biosciences And Genovis Enter Exclusive License Agreement To Advance Next-Generation IgG Protease